Altre lingue Traws Pharma, Inc.

Azioni

TRAW

US68232V8019

Tempo differito Nasdaq Altri mercati azionari 17:49:30 01/05/2024			Variaz. 5gg	Var. 1 gen.
0,668 ^USD	+1,21%		+4,15%	-10,41%

04/04	Traws Pharma, Inc. annuncia cambiamenti nell'ufficio dell'amministratore delegato	CI
04/04	Traws Pharma, Inc. annuncia cambiamenti nel Consiglio di Amministrazione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

North American Morning Briefing : Focus Turns to -2-	04/04
Traws Pharma, Inc. Announces Chief Executive Office Changes	04/04
Traws Pharma, Inc. Announces Board Changes	04/04
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics	02/04
Traws Pharma Announces New Employee Inducement Grants	02/04
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company	02/04
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc	02/04
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.	02/04
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines	01/04
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024	08/03
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	12/12
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	12/12
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's	11/12
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s	08/12
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s	08/12
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference	29/11
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference	28/11
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Posts Q3 Revenue $57,000	14/11
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results	14/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Traws Pharma, Inc.

Azioni

TRAW

US68232V8019

Altre lingue

Filtri